Press Release
<< Back
Verastem to Present at Keystone Symposia on PI3 Kinase
The details of the
Title: The dual PI3K/mTOR inhibitor VS-5584 displays potent
anticancer activities with preferential targeting of cancer stem cells
Date:
Session:
Poster Session 3
Poster Number: 3042
Location:
Quandary Peak
About
Forward-looking statements:
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Source:
Verastem, Inc.
Investor:
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media:
Kari
Watson, 781-235-3060
kwatson@macbiocom.com